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Abstract Abnormal Wnt signaling and impaired cell–cell
adhesion due to abnormal E-cadherin and b-catenin func-
tion have been implicated in many cancers, but have not
been fully explored in nasopharyngeal carcinoma. The aim
of this study was to analyze b-Catenin cellular location and
E-cadherin expression levels in nasopharyngeal carcinoma.
E-cadherin expression levels were also correlated with
clinical data and underlying pathology. b-Catenin and
E-cadherin expression were examined in 18 nasopharyn-
geal carcinoma and 7 non-tumoral inﬂammatory pharynx
tissues using immunohistochemical methods. Patient clin-
ical data were collected, and histological evaluation was
performed by hematoxylin/eosin staining. b-catenin was
detected in membrane and cytoplasm in all cases of naso-
pharyngeal carcinoma, regardless of histological type; in
non-tumoral tissues, however, b-catenin was observed only
in the membrane. As for E-cadherin expression levels,
strong staining was observed in most non-tumoral tissues,
but staining was only moderate in nasopharyngeal carci-
noma tissues. E-cadherin expression was associated with
b-catenin localization, study group, metastatic disease, and
patient outcomes. Reduced levels of E-cadherin protein
observed in nasopharyngeal carinoma may play an
important role in invasion and metastasis. Cytoplasmic
b-catenin in nasopharyngeal carcinoma may impair cell–
cell adhesion, promoting invasive behavior and a metastatic
tumor phenotype.
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Introduction
Nasopharyngeal carcinoma (NPC)—a distinct subtype of
head and neck squamous cell carcinoma with unique
epidemiology, clinical characteristics, etiology, and histo-
pathology [1]—is a rare malignant disease, although among
southern Chinese a peak incidence rate of around 20–30
cases per 100,000 has been reported [2]. NPC has been
classiﬁed by the World Health Organization (WHO) as both
a keranitizing and a non-keranitizing carcinoma. The non-
keranitizing form (WHO II), which includes differentiated
and undifferentiated non-keratinizing carcinoma, is more
common in southern China, where it accounts for over 97%
of NPCs [3]. Previous reports have shown that environ-
mental factors such as the intake of salted food, as well as
Epstein–Barr virus (EBV) infection and genetic factors, are
the major contributors to the etiology of NPC [4].
b-Catenin, originally identiﬁed on the basis of its asso-
ciation with cadherin adhesion molecules, is now widely
recognized as an essential element in the wingless Wnt
signaling cascade [5]. Wnt proteins bind to the receptors
belonging to the Frizzled (Fz) family. In the canonical
pathway, b-catenin activates an intracellular cascade that
involves the inhibition of glycogen synthase kinase 3b
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protein, ultimately resulting in the abnormal stabilization
of cytoplasmic b-catenin and its translocation to the
nucleus. Nuclear b-catenin then interacts with various
transcription factors to cause cellular proliferation and
differentiation. Abnormal Wnt signaling has been impli-
cated in a number of cancers including head and neck
carcinoma, lung cancer, colorectal cancer, melanoma, and
leukemia [6]. Although the role of the Wnt pathway in
NPC has not been fully explored, there is abundant evi-
dence that the aberrant Wnt signaling is involved in its
development [7, 8].
Cytoplasmic b-catenin plays a major role in the normal
cell by binding to the intracellular domain of E-cadherin to
maintain cell–cell adhesion. The expression of E-cadherin
has been found to be downregulated in many cancers
[9–11] including NPC [12]. It has been suggested that
E-cadherin downregulation may play a role in tumor pro-
gression and metastasis.
b-Catenin is signiﬁcantly associated with invasion and
metastasis of carcinomas of the head and neck, esophagus,
stomach,colon,liver,lung,breast,femalegenitalia,prostate,
bladder, and pancreas, as well as melanomas [11, 13–17].
Recently, several studies have pointed to the considerable
involvement of b-catenin not only in malignant transfor-
mation but also in the regulation of physiological functions,
and expression of this adhesion molecule in human naso-
pharyngeal carcinoma has been investigated [18, 19].
The present study sought to examine the possible role of
molecular cell–cell adhesion mechanisms in the oncogen-
esis and/or cytodifferentiation of differentiated and undif-
ferentiated non-keratinizing nasopharyngeal carcinoma.
Expression of b-catenin and E-cadherin was determined
by immunohistochemical analysis both in NPC patients
and in non-tumor patients with inﬂammatory diseases of
the pharynx.
Materials and methods
Patient samples and histological classiﬁcation
Eighteen patients with NPC (11 men and 7 women, aged
44–78) were diagnosed at the Virgen Macarena University
Hospital and the Infanta Luisa Hospital in Seville (Spain).
The study was approved by the Ethical Committee and
informed consent was obtained from all the participants in
the study. NPC samples and non-tumoral inﬂammatory
pharynx epithelium samples (control group; seven male
patients aged 19–55) were routinely ﬁxed in 10% buffered
formalin and embedded in parafﬁn. All the NPC patients
were classiﬁed according to WHO criteria (1975): 11
(61.1%) undifferentiated non-keratinizing carcinoma (type
3), 6 (33.4%) differentiated non-keratinizing carcinoma
(type 2), and 1 (5.5%) keratinizing carcinoma (type 1).
All biopsy samples were dehydrated and embedded in
parafﬁn. Histological evaluation was performed by two
pathologists using hematoxylin/eosin staining. Patient clin-
ical data and underlying pathologies are summarized in
Table 1.
Inmunohistochemical staining
Parafﬁn-embeddedtissueblocksfrom18NPCpatientsand7
patientswithnon-tumoralpharyngealinﬂammationwerecut
into 3 lm sections and placed on APES pre-coated slides.
Sections were deparafﬁnized in xylene and rehydrated in
alcohol and water. Immunohistochemistry (IHC) was per-
formed using the peroxidase–antiperoxidase technique after
microwave antigen retrieval procedure. Antibodies for
b-catenin and E-cadherin were purchased from ZYMED
Laboratories (ZYMED Laboratories, San Francisco, CA,
USA). Antibodies against b-catenin (1:200) and E-cadherin
(1:100) were overlaid on NPC tissue array sections and
incubated overnight at 4C. Secondary antibody incubation
was performed at room temperature for 30 min. Two
pathologists independently scored the results of immuno-
histochemical staining, and any discrepant scores were
reexamined to arrive at a consensus score.
For b-catenin, ??? indicates posivite staining in
membrane, cytoplasm and nucleus; ??, positive staining
in membrane and cytoplasm; ?, positive staining in
membrane. For E-cadherin, ? indicates 0–33% staining
cells, i.e. low staining; ??, 33–66% staining cells, i.e.
moderate staining; ???, 66–100% staining cells, i.e.
strong staining. Colorectal cancer and demoid tumor were
used as positive control and negative controls were
obtained by replacing primary antibodies by PBS.
Statistical analysis
Results, expressed as mean ± SEM, were analyzed using
Student0s test. Correlations between antigen immunoreac-
tivity, histopathological ﬁndings and clinical data were
evaluated by the Chi-square test. Differences were regar-
ded as signiﬁcant if p\0.05.
Results
Clinical data and histological classiﬁcation
Patient clinical data and underlying pathologies are sum-
marized in Table 1 and Fig. 1. All patients received
radiotherapy and chemotherapy (RT ? QT). No correla-
tion was found between clinical data (age, sex, recurrence,
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Age (years) Sex
a (f/m) Histologic classiﬁcation Metastasis Stage Treatment Evolution
1 47 m type 2 NPC Yes IV QT ? RT Recurrence
2 71 m type 2 NPC No II QT ? RT Dead
3 54 m type 2 NPC Yes II QT ? RT Recurrence
4 56 m type 2 NPC No II QT ? RT Disease-free
5 64 f type 3 NPC Yes III QT ? RT Dead
6 64 f type 1 NPC Yes II QT ? RT Recurrence
7 51 f type 2 NPC Yes II QT ? RT Dead
8 73 f type 3 NPC No I QT ? RT Dead
9 74 m type 3 NPC Yes II QT ? RT Disease-free
10 46 m type 3 NPC Yes III QT ? RT Dead
11 46 m type 3 NPC Yes II QT ? RT Dead
12 60 m type 3 NPC Yes II QT ? RT Recurrence
13 44 m type 3 NPC No III QT ? RT Disease-free
14 78 f type 2 NPC No II QT ? RT Disease-free
15 60 f type 3 NPC Yes III QT ? RT Disease-free
16 70 f type 3 NPC Yes III QT ? RT Disease-free
17 55 m type 3 NPC Yes III QT ? RT Dead
18 63 m type 3 NPC Yes IV QT ? RT Dead
18 45 m NT inﬂammatory of pharynx No Disease-free
20 29 m NT inﬂammatory of pharynx No Disease-free
21 53 m NT inﬂammatory of pharynx No Disease-free
22 21 m NT inﬂammatory of pharynx No Disease-free
23 36 m NT inﬂammatory of pharynx No Disease-free
24 55 m NT inﬂammatory of pharynx No Disease-free
25 19 m NT inﬂammatory of pharynx No Disease-free
a (f female, m male)
NT inﬂammation of pharynx0 Non-tumoral inﬂammation of pharynx, QT ? RT chemotherapy plus radiotherapy
Fig. 1 Hematoxylin/eosin staining. a (920) and b (940), keratiniz-
ing carcinoma (type 1) with squamous differentiation, showing
intercellular bridges, keratin deposits and pearly appearance. c (920)
and d (940), non-keratinizing squamous carcinoma (type 2): varied
degree of cell differentiation but no keratin production. e (920) and
f (940), undifferentiated non-keratinizing carcinoma (type 3):
lymphoepithelial proliferation, lymphoid cells breaking the tumor
into nests, syncytial pattern, and cells with round nuclei and
prominent nucleoli. g (920) and h (940), non-tumoral inﬂammation
of the pharynx
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numbers.
Immunohistochemical analysis of b-catenin
and E-cadherin
Protein expression was analyzed by immunohistochemical
staining for anti-b-catenin and anti-E-cadherin antibodies
in NPC and non-tumoral tissues. The seven non-tumoral
tissues showed equally strong membranous expression of
b-catenin, which was detected in both cytoplasm and
membrane in only 35% of cases. In contrast, b-catenin
expression was detected in the membrane and cytoplasm
of all NPC cases (Fig. 2). No signiﬁcant differences in
expression were recorded as a function of b-catenin local-
ization, tumor staging, metastasis, or patient outcomes.
With regard to the levels of E-cadherin expression,
strong staining was observed in 73% of non-tumoral tis-
sues, and moderate expression in 27% of cases. By con-
trast, moderate staining was observed in 90.5% of NPC
tissues, strong staining in 4.75% and low staining in 4.75%
of cases. Staining was moderate in all type 1 and type 3
NPC tissues, and in most (80%) type 2 NPC tissues
(Figs. 3, 4).
Whilst no correlation was noted between b-catenin
expression and clinical data (age, sex, evolution, and meta-
stasis), E-cadherinexpression wasassociated withb-catenin
localization (p = 0.006): elevated levels of E-cadherin
protein expression were observed when b-catenin was
localized in membrane, whilst moderate levels were recor-
ded when b-catenin was not only localized in membrane but
also in cytoplasm. A signiﬁcant correlation was also found
between E-cadherin expression and study group (p =
0.003): E-cadherin protein levels were higher in the control
group than in the NPC groups. E-cadherin protein levels
werealsoassociatedwithmetastasis(p = 0.002)andpatient
outcomes (p = 0.013): NPC patients with poor prognosis
displayed lower levels of E-cadherin expression than those
displaying neither recurrence nor metastasis.
Discussion
NPC tumor cells are very likely to invade surrounding
tissue or metastasize to cervical lymph nodes in the early
stages of tumor development [20]. However, the major
relevant mechanism remains unknown. Many factors may
be involved in local invasion and distant metastasis,
including cell–cell adhesion molecules, matrix metallo-
proteinase family and cytokines, which can alter the
mobility and distribution of tumoral cells [21, 22].
b-Catenin contributes both to cell–cell adhesion and to
the Wnt signaling pathway [23, 24]. The cadherin–catenin
complex is a group of membrane proteins that is important
in cell–cell adhesion, tumor suppression, cell differentia-
tion and cell migration. Some reports have suggested that
downregulated expression of b-catenin might play a role in
early and late tumor invasion and metastasis [25, 26].
Downregulation of b-catenin has been found to be closely
related to advanced clinical disease and short survival in
NPC patients [12]. The present study, however, noted no
alteration in b-catenin protein expression, and no
Fig. 2 Immunohistochemical staining for b-catenin expression in 18
nasopharyngeal carcinoma tissues. In all cases b-catenin expression
was determined in membrane and cytoplasm. a (940), keratinizing
carcinoma (type 1). b (940), differentiated non-keratinizing
carcinoma (type 2). c (940), undifferentiated non-keratinizing
carcinoma (type 3). d (940), non-tumoral pharyngeal inﬂammation.
Positive controls for nuclear b-catenin: e (940), colorectal carcinoma.
f (940), desmoid tumor
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123correlation between its expression and NPC patient out-
comes. These results suggest that b-catenin may not in
itself be a major factor for NPC tumor cell invasion and
metastasis. Here, b-catenin protein levels were evaluated
using inmunohistochemical staining, a semi-quantitative
technique enabling assessment of proteins in parafﬁn-
embedded tissues. Further research will evaluate b-catenin
expression levels using the western blot technique, with a
view to measuring possible alterations in b-catenin protein
levels in fresh tissue.
b-Catenin is also involved in the Wnt canonical pathway
as a transcriptional activator [23, 24]. The inhibition of
glycogen synthase kinase (GSK-3b) and the adenomatous
polyposis coli (APC) protein ultimately results in the sta-
bilization and nuclear translocation of cytoplastic b-cate-
nin. Finally, nuclear b-catenin interacts with various
transcription factors to cause proliferation and differentia-
tion. However, further research is required to link altered
b-catenin levels and development of NPC. Here, b-catenin
was detected in membrane and cytoplasm, but not in the
nucleus. Although Zheng et al. [12] found nuclear b-cate-
nin in ﬁve cases of undifferentiated NPC, other authors
have failed to detect nuclear b-catenin. Li et al. [27]
observed increased membrane b-catenin but no nuclear
b-catenin in 42 NPC patients; by contrast, Zhi et al. [28]
found no nuclear or cytoplasmic b-catenin in any NPC
tissues studied. In the present study, failure to detect
nuclear b-catenin suggests that the canonical Wnt pathway
may be inactivated in this type of cancer. However,
this cannot be categorically conﬁrmed, since stabilized
b-cateninwasdetectedincytoplasm.Furtherresearchwillbe
necessarytodeterminewhethertheWntpathwayisactivated
by overexpression of its receptors or silencing of its sup-
pressors,andalsotoinvestigatethepossibleactivationofthe
non-canonical Wnt pathway that includes signaling through
calcium ﬂux, JNK and heterotrimeric G proteins.
E-cadherin is essential for normal cell function, and
downregulated in processes such as wound healing,
allowing epithelial cells to move and cover denuded tissue
[29]. E-cadherin, localized to the zonula adherens, com-
plexes with catenins b and c; b- and c-catenins in turn bind
to a-catenin which attaches to the actin ﬁlaments in the cell
cytoskeleton [30]. E-cadherin is thought to act as a tumor
suppressor, since it suppresses invasion and metastasis
[31]. Low expression of E-cadherin has been shown to
predict poor outcome in oral cavity and laryngeal carci-
nomas [32, 33]. In this study, moderate E-cadherin
expression was detected in all type 1 and type 3 NPC tis-
sues and in almost all type 2 tissues. By contrast, strong
Fig. 3 Immunohistochemical
staining for E-cadherin
expression in 18
nasopharyngeal carcinoma
tissues. a (940), keratinizing
carcinoma. b (940),
differentiated non-keratinizing
carcinoma (type 2). c (940),
undifferentiated non-
keratinizing carcinoma (type 3).
a–c Moderate staining for
E-cadherin protein, d (940)
non-tumoral pharyngeal
inﬂammation; strong staining
for E-cadherin protein
Fig. 4 E-cadherin protein expression in nasopharyngeal carcinoma
tissues and non-tumoral inﬂammatory pharynx tissues. Data are
expressed as mean of cases per study group (%)
Eur Arch Otorhinolaryngol (2011) 268:1335–1341 1339
123E-cadherin expression was detected in non-tumoral tissues,
so that downregulation of E-cadherin expression in NPC
tissues may indicate a greater capacity for invasion and
metastasis. Indeed, a positive correlation was observed
between E-cadherin expression levels, the presence of
lymphnodemetastasis inNPCtissuesandpatientoutcomes.
In this respect, several studies have shown that diminished
E-cadherin expression is a good predictor of concurrent
lymphnodemetastasisinlaryngealcarcinoma,andheadand
neck squamous cell cancer [34–36]. Zhi et al. [28] noted a
correlation between reduced E-cadherin expression and
NPC lymph node metastasis. In some cancer cells, aberrant
gene promoter methylation of E-cadherin may be responsi-
ble for the decreased expression of E-cadherin [34, 35];
future research will therefore focus on possible epigenetic
changes due to promoter hypermethylation in NPC tissues.
Finally, a correlation was observed between E-cadherin
protein levels and b-catenin localization, low levels being
associated with b-catenin in cytoplasm. Other studies of
head and neck squamous cell carcinomas report loss of
membranous E-cadherin and b-catenin expression and
increased cytoplasmic expression, irrespective of the pri-
mary carcinoma or nodal carcinoma involved [37].
Impairment of cell–cell adhesion is an essential step in the
progression from localized malignancy to stromal and
vascular invasion and metastatic disease. This impairment
is achieved through a variety of mechanisms involving the
cadherin/catenin complex [38].
The results obtained here suggest an enhancement of the
potential ability of cancer cells to disperse, a preliminary
step in local invasion. A better knowledge of the regulation
of the cadherin–catenin system is required for the preven-
tion or treatment of nasopharyngeal carcinoma.
In conclusion, reduced levels of E-cadherin protein in
NPC may play an important role in invasion and metastasis.
Cytoplasmic b-catenin in NPC leads to impaired cell–cell
adhesion, promoting invasive behavior and a metastatic
tumor phenotype. Further research is required to clarify the
involvement of b-catenin in the mechanism associated with
malignant transformation in nasopharyngeal tissues.
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